FDA Gives Full Approval to Pembrolizumab in dMMR/MSI-H Solid TumorsMarch 29th 2023
Based on results from the phase 2 KEYNOTE-158, KEYNOTE-164, and KEYNOTE-051 trials, the FDA has given full approval to pembrolizumab for patients with microsatellite instability-high or mismatch repair deficient solid tumors.
FDA Grants Orphan Drug Designation to Tirabrutinib in Primary CNS LymphomaMarch 29th 2023
Investigators are assessing tirabrutinib, which received orphan drug designation from the FDA, as a treatment for patients with relapsed or refractory primary central nervous system lymphoma in the phase 2 PROSPECT study.
Updated Data and Groundbreaking Research Lead to an Exciting 2023 ASCO GIMarch 29th 2023
Co-editor-in-Chief Howard S. Hochster, MD, highlights the most exciting developments from the 2023 Gastrointestinal Cancer Symposium hosted by the American Society of Clinical Oncology (ASCO).
Pembrolizumab Combo Yields Benefits in pMMR/dMMR Advanced Endometrial CancerMarch 28th 2023
Pembrolizumab plus chemotherapy followed by maintenance pembrolizumab reduced the risk of death or disease progression in patients with mismatch repair proficient or deficient advanced endometrial cancer.
Post-Surgical Radiation Omission did not Raise Breast Cancer Distant RecurrenceMarch 28th 2023
Overall survival after 10 years appears to be comparable regardless of whether patients 65 years or older received irradiation following surgery for low-risk, hormone receptor–positive breast cancer.
Questionnaires Are Comparable in Assessing Lymphedema in Endometrial CancerMarch 27th 2023
The lower extremity lymphedema screening questionnaire and gynecological cancer lymphedema questionnaire appear to demonstrate comparable utility in assessing lymphedema in patients with advanced endometrial cancer.
Dose Modification of Maintenance Niraparib May Not Impact PFS in Ovarian CancerMarch 27th 2023
A post hoc analysis demonstrated that dose modifications to frontline niraparib maintenance therapy did not affect progression-free survival among patients with newly diagnosed, advanced ovarian cancer.
Addition of Dual Checkpoint Blockade Inhibition Improves PFS in Ovarian CancerMarch 27th 2023
Durvalumab plus tremelimumab in combination with neoadjuvant chemotherapy did not yield any major adverse effects in patients with newly diagnosed advanced ovarian cancer in the phase 2 KGOG3046 trial.
Adding HIPEC to Cytoreductive Surgery Does Not Impact HRQOL in Ovarian CancerMarch 25th 2023
Vadim Gushchin, MD, says that treatment with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy should not be limited by concerns of negatively impacting health-related quality of life in ovarian cancer.
PSA Cut-Point Indicates When to Start Salvage Radiotherapy in Prostate CancerMarch 24th 2023
An expert from Dana-Farber Cancer Institute indicates that patients with prostate cancer who have 1 risk factor should undergo salvage radiotherapy following radical prostatectomy before their prostate-specific antigen level rises above 0.25 ng/ml.